0001157523-21-001322.txt : 20211103 0001157523-21-001322.hdr.sgml : 20211103 20211103163218 ACCESSION NUMBER: 0001157523-21-001322 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211103 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211103 DATE AS OF CHANGE: 20211103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CROSS COUNTRY HEALTHCARE INC CENTRAL INDEX KEY: 0001141103 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HELP SUPPLY SERVICES [7363] IRS NUMBER: 134066229 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33169 FILM NUMBER: 211375972 BUSINESS ADDRESS: STREET 1: 6551 PARK OF COMMERCE BOULEVARD, N.W. CITY: BOCA RATON STATE: FL ZIP: 33487 BUSINESS PHONE: 8003472264 MAIL ADDRESS: STREET 1: 6551 PARK OF COMMERCE BOULEVARD, N.W. CITY: BOCA RATON STATE: FL ZIP: 33487 FORMER COMPANY: FORMER CONFORMED NAME: CROSS COUNTRY INC DATE OF NAME CHANGE: 20010521 8-K 1 a52520247.htm CROSS COUNTRY HEALTHCARE, INC. 8-K

UNITED STATES 
 SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
 
 
FORM 8-K
 
 
 
CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) November 3, 2021
 graphic
 
 
 
CROSS COUNTRY HEALTHCARE INC
(Exact name of registrant as specified in its charter)
 
 

Delaware
0-33169
13-4066229
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
 
6551 Park of Commerce Boulevard, N.W., Boca Raton, Florida 33487
(Address of Principal Executive Office) (Zip Code)

(561) 998-2232
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class Trading Symbol Name of each exchange on which registered
Common stock, par value $0.0001 per share
 CCRN
 The Nasdaq Stock Market LLC

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section 2 – Financial Information
 
Item 2.02     Results of Operations and Financial Condition
 
(a)  On November 3, 2021, Cross Country Healthcare, Inc. (“the Company”) issued a press release announcing results for the quarter ended September 30, 2021, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K. This information is being furnished under Item 2.02 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.

Section 7 – Regulation FD
 
Item 7.01     Regulation FD Disclosure
 
Incorporated by reference is a press release issued by the Company on November 3, 2021, which is attached hereto as Exhibit 99.1. This information is being furnished under Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section.
 
Section 9 – Financial Statements and Exhibits
 
Item 9.01     Financial Statements and Exhibits
 
(d) Exhibits

 
Exhibit
Description
     
 
 
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 
CROSS COUNTRY HEALTHCARE, INC.
     
     
 
By:
/s/ William J. Burns
   
William J. Burns
Dated:     November 3, 2021
  
Executive Vice President & Chief Financial Officer

EX-99.1 2 a52520247ex991.htm EXHIBIT 99.1
Exhibit 99.1

Cross Country Healthcare Announces Third Quarter 2021 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--November 3, 2021--Cross Country Healthcare, Inc. (the "Company") (Nasdaq: CCRN) today announced financial results for its third quarter ended September 30, 2021.

SELECTED FINANCIAL INFORMATION:

 

 

 

Variance

Variance

 

 

 

Q3 2021 vs

Q3 2021 vs

Dollars are in thousands, except per share amounts

Q3 2021

Q3 2020

Q2 2021

Revenue

$

374,905

 

 

93

 

%

13

 

%

Gross profit margin*

22.4

 

%

(230)

 

bps

50

 

bps

Net income attributable to common shareholders

$

23,433

 

 

1,857

 

%

103

 

%

Diluted EPS

$

0.62

 

 

$

0.66

 

 

$

0.31

 

 

Adjusted EBITDA*

$

30,127

 

 

250

 

%

24

 

%

Adjusted EBITDA margin*

8.0

 

%

360

 

bps

70

 

bps

Adjusted EPS*

$

0.61

 

 

$

0.49

 

 

$

0.14

 

 

Cash flows used in operations

$

(2,831)

 

 

67

 

%

(118)

 

%

* Refer to accompanying tables and discussion of non-GAAP (Generally Accepted Accounting Principles) financial measures below.

Business Highlights

  • Year-to-date revenue exceeded $1.0 billion for the first time in the Company's history
  • Year-over-year and sequential increase in volume across all segments
  • Third quarter financial performance exceeded guidance across all areas
  • Adjusted EBITDA margin exceeded 8% for the second time this year
  • Recognized as one of the top four staffing and recruiting employers for women
  • Strong double digit growth from Cross Country Workforce Solutions Group

“Our performance demonstrates the success we are having in bringing clinicians to the bedside across the nation,” said Kevin Clark, Co-Founder and CEO. He continued, “Higher bill rates are really only part of the story, as the investments we have made in people and technology, along with the many changes we have made to core processes, allow us to execute more effectively. We have fundamentally transformed this company and believe we have the ability to continue to grow the number of clinicians on assignment.”

Third quarter consolidated revenue was $374.9 million, an increase of 93% year-over-year and 13% sequentially. Consolidated gross profit margin was 22.4%, down 230 basis points year-over-year and up 50 basis points sequentially. Net income attributable to common shareholders was $23.4 million compared to a net loss of $1.3 million in the prior year and net income of $11.5 million in the prior quarter. Diluted earnings per share (EPS) was $0.62 per share compared to a loss of $0.04 per share in the prior year and income of $0.31 per share in the prior quarter. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) was $30.1 million or 8.0% of revenue, as compared with $8.6 million or 4.4% of revenue in the prior year, and $24.3 million or 7.3% of revenue in the prior quarter. Adjusted EPS was $0.61 compared to $0.12 in the prior year and $0.47 in the prior quarter.

For the nine months ended September 30, 2021, consolidated revenue was $1.0 billion, an increase of 67% year-over-year. Consolidated gross profit margin was 22.0%, down 190 basis points year-over-year. Net income attributable to common shareholders was $54.4 million, or 1.46 per diluted share, compared to a loss of $17.6 million, or 0.49 per diluted share, in the prior year. Adjusted EBITDA was $81.1 million or 7.8% of revenue, as compared with $24.8 million or 4.0% of revenue in the prior year. Adjusted EPS was $1.66 compared to $0.27 in the prior year.

Quarterly Business Segment Highlights

Nurse and Allied Staffing

Revenue was $356.1 million, an increase of 101% year-over-year and 13% sequentially. Contribution income was $40.6 million, an increase compared to $17.9 million in the prior year and $35.3 million in the prior quarter. Average field contract personnel on a full-time equivalent (FTE) basis were 9,003 as compared with 5,403 in the prior year and 7,578 in the prior quarter. Revenue per FTE per day was $425 compared to $353 in the prior year and $454 in the prior quarter. The increase in the average number of FTEs was primarily due to headcount growth in travel nurse and allied, as well as additional headcount resulting from the Cross Country Workforce Solutions Group (WSG) acquisition. In the third quarter, average bill rates rose slightly as we continued to experience higher demand and bill rates related to both COVID-19 and non-COVID-19 assignments, with a record level of demand across a wide range of specialties. Throughout the coronavirus pandemic (COVID-19), we have worked with our clients to adjust bill rates, both increasing and decreasing rates as necessary, to provide critical healthcare professionals.

Physician Staffing

Revenue was $18.8 million, an increase of 14% year-over-year and 20% sequentially. Contribution income was $0.9 million, an increase compared to $0.8 million in the prior year and $0.6 million in the prior quarter. Total days filled were 12,187 as compared with 9,682 in the prior year and 9,775 in the prior quarter. Revenue per day filled was $1,540 as compared with $1,699 in the prior year and $1,600 in the prior quarter. The increase in revenue was primarily due to an increase in volume in both primary care physicians and nurse practitioners. The increase in contribution income was driven by higher revenue, partially offset by higher direct costs.

Cash Flow and Balance Sheet Highlights

Cash flow used in operations for the quarter was $2.8 million compared to $8.5 million in the prior year and cash flow provided by operations of $15.5 million in the prior quarter, primarily due to strong sequential revenue growth which resulted in a $122.9 million increase in receivables since the start of the year. For the nine months ended September 30, 2021, cash flow used in operations was $12.3 million compared to cash flow provided by operations of $25.3 million in the prior year. Days' sales outstanding was 61 days as of September 30, 2021, down 3 days year-over-year and up 3 days since the beginning of the current year, primarily due to the timing of revenue recognized throughout the quarter given the strong monthly sequential growth through the third quarter.

At September 30, 2021, the Company had $0.8 million in cash and cash equivalents and $99.7 million principal balance on its term loan, with $4.0 million of borrowings drawn under its asset-based loan facility (ABL), and $18.5 million of letters of credit outstanding. Availability under the ABL is subject to a borrowing base, which was $149.2 million as of September 30, 2021, with $126.7 million available for borrowing as of September 30, 2021.

Outlook for Fourth Quarter 2021

The guidance below applies to management’s expectations for the fourth quarter of 2021.

 

Q4 2021 Range

 

Year-over-Year

 

Sequential

Change

 

Change

 

 

 

 

 

 

Revenue

$580 million - $590 million

 

169% - 174%

 

55% - 57%

 

 

 

 

 

 

Gross Profit Margin*

22.2% - 22.7%

 

(300) bps - (250) bps

 

(20) bps - 30 bps

 

 

 

 

 

 

Adjusted EBITDA*

$63.0 million - $68.0 million

 

448% - 491%

 

109% - 126%

 

 

 

 

 

 

Adjusted EPS*

$1.01 - $1.11

 

$0.82 - $0.92

 

$0.40 - $0.50

* Refer to discussion of non-GAAP financial measures below.

The above estimates are based on current management expectations and, as such, are forward-looking and actual results may differ materially. The above ranges do not include the potential impact of any future divestitures, mergers, acquisitions, or other business combinations, changes in debt structure, or future share repurchases.

As we reported at the end of the second quarter 2021, we expected bill rates for our travel division to decline sequentially. Instead, average bill rates rose slightly during the third quarter and we expect them to rise again in the fourth quarter of 2021. We expect the pandemic to continue impacting our financial performance through at least the end of the current fiscal year. However, while COVID-19 has driven up bill rates with regional spikes in demand related to the Delta variant, the impact from states and healthcare systems enacting vaccination mandates is exacerbating an already tight supply market, and we are also experiencing growing needs in non-COVID assignments resulting in increased demand from clinicians leaving the bedside due to burnout or retirement.

See accompanying non-GAAP financial measures and tables below.

INVITATION TO CONFERENCE CALL

The Company will hold its quarterly conference call on Wednesday, November 3, 2021, at 5:00 P.M. Eastern Time to discuss its third quarter 2021 financial results. This call will be webcast live and can be accessed at the Company’s website at ir.crosscountryhealthcare.com or by dialing 888-566-1290 from anywhere in the U.S. or by dialing 773-799-3776 from non-U.S. locations - Passcode: Cross Country. A replay of the webcast will be available from November 3rd through November 17th at the Company’s website and a replay of the conference call will be available by telephone by calling 800-385-2541 from anywhere in the U.S. or 203-369-3263 from non-U.S. locations - Passcode: 2021.

ABOUT CROSS COUNTRY HEALTHCARE

Cross Country Healthcare, Inc. (CCH) is a leader in providing total talent management including strategic workforce solutions, contingent staffing, permanent placement, and consultative services for healthcare customers. Leveraging our 35 years of industry expertise and insight, CCH solves complex labor-related challenges for customers while providing high-quality outcomes and exceptional patient care. As a multi-year Best of Staffing® Award winner, CCH is committed to an exceptionally high level of service to both our clients and our healthcare professionals. CCH was the first publicly traded staffing firm to obtain The Joint Commission Certification, which it still holds with a Letter of Distinction. CCH was recently listed as one of the top four staffing and recruiting employers for women by InHerSights in October 2021 and earned Energage’s inaugural 2021 Top Workplaces USA award in February 2021. CCH has a longstanding history of investing in its diversity, equality, and inclusion strategic initiatives as a key component of the organization’s overall corporate social responsibility program which is closely aligned with its core values to create a better future for its people, communities, the planet, and its shareholders.

Copies of this and other news releases as well as additional information about the Company can be obtained online at ir.crosscountryhealthcare.com. Shareholders and prospective investors can also register to automatically receive the Company’s press releases, filings with the Securities and Exchange Commission (SEC), and other notices by e-mail.

NON-GAAP FINANCIAL MEASURES

This press release and the accompanying financial statement tables reference non-GAAP financial measures, such as gross profit margin, adjusted EBITDA, and adjusted EPS. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with U.S. GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes they are useful to investors when evaluating the Company's performance as they exclude certain items that management believes are not indicative of the Company's future operating performance. Pro forma measures, if applicable, are adjusted to include the results of our acquisitions, and exclude the results of divestments, as if the transactions occurred in the beginning of the periods mentioned. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.

FORWARD LOOKING STATEMENTS

In addition to historical information, this press release contains statements relating to our future results (including certain projections and business trends) that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act, and are subject to the "safe harbor" created by those sections. Forward-looking statements consist of statements that are predictive in nature, depend upon or refer to future events. Words such as "expects", "anticipates", "intends", "plans", "believes", "estimates", "suggests", "appears", "seeks", "will", "could", and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, but are not limited to, the following: the potential impacts of the COVID-19 pandemic on our business, financial condition, and results of operations, our ability to attract and retain qualified nurses, physicians and other healthcare personnel, costs and availability of short-term housing for our travel healthcare professionals, demand for the healthcare services we provide, both nationally and in the regions in which we operate, the functioning of our information systems, the effect of cyber security risks and cyber incidents on our business, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, our clients’ ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, including our ability to successfully integrate acquired businesses and realize synergies from such acquisitions, the effect of potential liabilities, losses, or other exposures in connection with the WSG acquisition, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors set forth in Item 1A. "Risk Factors" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and in our other filings with the SEC. You should consult any further disclosures the Company makes on related subjects in its filings with the SEC.

Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s opinions only as of the date of this press release. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, and/or (iv) our strategy, which is based in part on this analysis, will be successful. The Company undertakes no obligation to update or revise forward-looking statements. All references to "we", "us", "our", or "Cross Country" in this press release mean Cross Country Healthcare, Inc. and its subsidiaries.

Cross Country Healthcare, Inc.

Consolidated Statements of Operations

(Unaudited, amounts in thousands, except per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

September 30,

 

 

September 30,

 

 

June 30,

 

 

September 30,

 

September 30,

 

2021

 

 

2020

 

 

2021

 

 

2021

 

2020

 

 

 

 

 

 

 

Revenue from services

$

374,905

 

 

 

$

193,968

 

 

 

$

331,827

 

 

 

$

1,035,973

 

 

$

620,811

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Direct operating expenses

291,111

 

 

 

145,965

 

 

 

259,237

 

 

 

808,124

 

 

472,471

 

Selling, general and administrative expenses

52,847

 

 

 

40,804

 

 

 

50,344

 

 

 

149,518

 

 

128,939

 

Bad debt expense

1,441

 

 

 

946

 

 

 

466

 

 

 

2,411

 

 

2,383

 

Depreciation and amortization

2,680

 

 

 

3,247

 

 

 

2,199

 

 

 

7,132

 

 

10,472

 

Acquisition and integration-related costs

61

 

 

 

—

 

 

 

924

 

 

 

985

 

 

77

 

Restructuring costs

318

 

 

 

2,316

 

 

 

835

 

 

 

2,391

 

 

5,210

 

Impairment charges

—

 

 

 

1,071

 

 

 

1,921

 

 

 

2,070

 

 

16,082

 

Total operating expenses

348,458

 

 

 

194,349

 

 

 

315,926

 

 

 

972,631

 

 

635,634

 

Income (loss) from operations

26,447

 

 

 

(381

)

 

 

15,901

 

 

 

63,342

 

 

(14,823

)

Other expenses (income):

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

2,182

 

 

 

608

 

 

 

1,196

 

 

 

4,049

 

 

2,219

 

Other income, net

(375

)

 

 

(10

)

 

 

(204

)

 

 

(616

)

 

(46

)

Income (loss) before income taxes

24,640

 

 

 

(979

)

 

 

14,909

 

 

 

59,909

 

 

(16,996

)

Income tax expense (benefit)

1,207

 

 

 

169

 

 

 

3,361

 

 

 

5,480

 

 

(32

)

Consolidated net income (loss)

23,433

 

 

 

(1,148

)

 

 

11,548

 

 

 

54,429

 

 

(16,964

)

Less: Net income attributable to noncontrolling interest in subsidiary

—

 

 

 

186

 

 

 

—

 

 

 

—

 

 

610

 

Net income (loss) attributable to common shareholders

$

23,433

 

 

 

$

(1,334

)

 

 

$

11,548

 

 

 

$

54,429

 

 

$

(17,574

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share attributable to common shareholders - Basic

$

0.63

 

 

 

$

(0.04

)

 

 

$

0.32

 

 

 

$

1.49

 

 

$

(0.49

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share attributable to common shareholders - Diluted

$

0.62

 

 

 

$

(0.04

)

 

 

$

0.31

 

 

 

$

1.46

 

 

$

(0.49

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

36,963

 

 

 

36,176

 

 

 

36,625

 

 

 

36,593

 

 

36,058

 

Diluted

37,582

 

 

 

36,176

 

 

 

37,203

 

 

 

37,276

 

 

36,058

 

Cross Country Healthcare, Inc.

Reconciliation of Non-GAAP Financial Measures

(Unaudited, amounts in thousands, except per share data)

 

 

Three Months Ended

 

 

Nine Months Ended

 

September 30,

 

 

September 30,

 

 

June 30,

 

 

September 30,

 

September 30,

 

2021

 

 

2020

 

 

2021

 

 

2021

 

2020

Adjusted EBITDA:a

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to common shareholders

$

23,433

 

 

 

$

(1,334

)

 

 

$

11,548

 

 

 

$

54,429

 

 

$

(17,574

)

Interest expense

2,182

 

 

 

608

 

 

 

1,196

 

 

 

4,049

 

 

2,219

 

Income tax expense (benefit)

1,207

 

 

 

169

 

 

 

3,361

 

 

 

5,480

 

 

(32

)

Depreciation and amortization

2,680

 

 

 

3,247

 

 

 

2,199

 

 

 

7,132

 

 

10,472

 

Acquisition and integration-related costsb

61

 

 

 

—

 

 

 

924

 

 

 

985

 

 

77

 

Restructuring costsc

318

 

 

 

2,316

 

 

 

835

 

 

 

2,391

 

 

5,210

 

Legal settlements and feesd

(1,556

)

 

 

837

 

 

 

28

 

 

 

(1,153

)

 

2,398

 

Impairment chargese

—

 

 

 

1,071

 

 

 

1,921

 

 

 

2,070

 

 

16,082

 

Other income, net

(375

)

 

 

(10

)

 

 

(204

)

 

 

(616

)

 

(46

)

Equity compensation

1,771

 

 

 

1,064

 

 

 

2,137

 

 

 

5,257

 

 

4,063

 

Applicant tracking system costsf

406

 

 

 

444

 

 

 

315

 

 

 

1,096

 

 

1,343

 

Net income attributable to noncontrolling interest in subsidiaryg

—

 

 

 

186

 

 

 

—

 

 

 

—

 

 

610

 

Adjusted EBITDAa

$

30,127

 

 

 

$

8,598

 

 

 

$

24,260

 

 

 

$

81,120

 

 

$

24,822

 

Adjusted EBITDA margina

8.0

%

 

 

4.4

%

 

 

7.3

%

 

 

7.8

%

 

4.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EPS:h

 

 

 

 

 

 

 

 

 

 

 

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to common shareholders

$

23,433

 

 

 

$

(1,334

)

 

 

$

11,548

 

 

 

$

54,429

 

 

$

(17,574

)

Non-GAAP adjustments - pretax:

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition and integration-related costsb

61

 

 

 

—

 

 

 

924

 

 

 

985

 

 

77

 

Restructuring costsc

318

 

 

 

2,316

 

 

 

835

 

 

 

2,391

 

 

5,210

 

Legal settlements and feesd

(1,556

)

 

 

837

 

 

 

28

 

 

 

(1,153

)

 

2,398

 

Impairment charges (excluding rebranding impacts)e

—

 

 

 

1,071

 

 

 

1,921

 

 

 

2,070

 

 

16,082

 

Rebranding impairments and accelerated amortizatione

—

 

 

 

938

 

 

 

—

 

 

 

—

 

 

3,075

 

Applicant tracking system costsf

406

 

 

 

444

 

 

 

315

 

 

 

1,096

 

 

1,343

 

Nonrecurring income tax adjustmentsi

—

 

 

 

—

 

 

 

1,942

 

 

 

1,942

 

 

313

 

Tax impact of non-GAAP adjustments

(1

)

 

 

(20

)

 

 

(11

)

 

 

(14

)

 

(990

)

Adjusted net income attributable to common shareholders - non-GAAP

$

22,661

 

 

 

$

4,252

 

 

 

$

17,502

 

 

 

$

61,746

 

 

$

9,934

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares - basic, GAAP

36,963

 

 

 

36,176

 

 

 

36,625

 

 

 

36,593

 

 

36,058

 

Dilutive impact of share-based paymentsj

619

 

 

 

228

 

 

 

578

 

 

 

683

 

 

253

 

Adjusted weighted average common shares - diluted, non-GAAP

37,582

 

 

 

36,404

 

 

 

37,203

 

 

 

37,276

 

 

36,311

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation:

 

 

 

 

 

 

 

 

 

 

 

 

Diluted EPS, GAAP

$

0.62

 

 

 

$

(0.04

)

 

 

$

0.31

 

 

 

$

1.46

 

 

$

(0.49

)

Non-GAAP adjustments - pretax:

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition and integration-related costsb

—

 

 

 

—

 

 

 

0.03

 

 

 

0.03

 

 

—

 

Restructuring costsc

0.01

 

 

 

0.06

 

 

 

0.02

 

 

 

0.06

 

 

0.14

 

Legal settlements and feesd

(0.03

)

 

 

0.03

 

 

 

—

 

 

 

(0.02

)

 

0.07

 

Impairment charges (excluding rebranding impacts)e

—

 

 

 

0.03

 

 

 

0.05

 

 

 

0.05

 

 

0.45

 

Rebranding impairments and accelerated amortizatione

—

 

 

 

0.03

 

 

 

—

 

 

 

—

 

 

0.09

 

Applicant tracking system costsf

0.01

 

 

 

0.01

 

 

 

0.01

 

 

 

0.03

 

 

0.03

 

Nonrecurring income tax adjustmentsi

—

 

 

 

—

 

 

 

0.05

 

 

 

0.05

 

 

0.01

 

Tax impact of non-GAAP adjustments

—

 

 

 

—

 

 

 

—

 

 

 

—

 

 

(0.03

)

Adjusted EPS, non-GAAPh

$

0.61

 

 

 

$

0.12

 

 

 

$

0.47

 

 

 

$

1.66

 

 

$

0.27

 

 

Cross Country Healthcare, Inc.

Consolidated Balance Sheets

(Unaudited, amounts in thousands)

 

 

September 30,

 

 

December 31,

 

2021

 

 

2020

 

 

 

 

 

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

$

842

 

 

 

$

1,600

 

Accounts receivable, net

301,040

 

 

 

170,003

 

Prepaid expenses

3,418

 

 

 

5,455

 

Insurance recovery receivable

4,655

 

 

 

4,698

 

Other current assets

3,318

 

 

 

1,355

 

Total current assets

313,273

 

 

 

183,111

 

Property and equipment, net

14,877

 

 

 

12,351

 

Operating lease right-of-use assets

8,064

 

 

 

10,447

 

Goodwill

112,990

 

 

 

90,924

 

Trade names, indefinite-lived

5,900

 

 

 

5,900

 

Other intangible assets, net

44,145

 

 

 

34,831

 

Other non-current assets

21,171

 

 

 

19,409

 

Total assets

$

520,420

 

 

 

$

356,973

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable and accrued expenses

$

73,033

 

 

 

$

49,877

 

Accrued employee compensation and benefits

54,875

 

 

 

35,540

 

Current portion of debt

3,426

 

 

 

2,425

 

Operating lease liabilities - current

4,362

 

 

 

4,509

 

Current portion of earnout liability

7,500

 

 

 

—

 

Other current liabilities

1,466

 

 

 

1,072

 

Total current liabilities

144,662

 

 

 

93,423

 

Long-term debt, less current portion

98,665

 

 

 

53,408

 

Operating lease liabilities - non-current

12,280

 

 

 

15,234

 

Non-current deferred tax liabilities

9,388

 

 

 

6,592

 

Long-term accrued claims

25,521

 

 

 

25,412

 

Long-term contingent consideration

7,500

 

 

 

—

 

Other long-term liabilities

5,605

 

 

 

7,995

 

Total liabilities

303,621

 

 

 

202,064

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

Common stock

4

 

 

 

4

 

Additional paid-in capital

318,415

 

 

 

310,388

 

Accumulated other comprehensive loss

(1,312

)

 

 

(1,280

)

Accumulated deficit

(100,308

)

 

 

(154,737

)

Total Cross Country Healthcare, Inc. stockholders' equity

216,799

 

 

 

154,375

 

Noncontrolling interest in subsidiary

—

 

 

 

534

 

Total stockholders' equity

216,799

 

 

 

154,909

 

Total liabilities and stockholders' equity

$

520,420

 

 

 

$

356,973

 

 

Cross Country Healthcare, Inc.

Segment Datak

(Unaudited, amounts in thousands)

 

 

Three Months Ended

 

Year-over-
Year

 

Sequential

 

September 30,


% of

 

September 30,


% of

 

June 30,


% of

 

% change

 

% change

 

2021


Total

 

2020


Total

 

2021


Total

 

Fav (Unfav)

 

Fav (Unfav)

 

 


 

 

 


 

 

 


 

 

 

 

 

Revenue from services:

 


 

 

 


 

 

 


 

 

 

 

 

Nurse and Allied Staffing

$

356,139

 


95

%

 

$

177,516

 


91

%

 

$

316,188

 


95

%

 

101

%

 

13

%

Physician Staffing

18,766

 


5

%

 

16,452

 


9

%

 

15,639

 


5

%

 

14

%

 

20

%

 

$

374,905

 


100

%

 

$

193,968

 


100

%

 

$

331,827

 


100

%

 

93

%

 

13

%

 

 


 

 

 


 

 

 


 

 

 

 

 

Contribution income:l

 


 

 

 


 

 

 


 

 

 

 

 

Nurse and Allied Staffing

$

40,645

 


 

 

$

17,925

 


 

 

$

35,284

 


 

 

127

%

 

15

%

Physician Staffing

910

 


 

 

827

 


 

 

562

 


 

 

10

%

 

62

%

 

41,555

 


 

 

18,752

 


 

 

35,846

 


 

 

122

%

 

16

%

 

 


 

 

 


 

 

 


 

 

 

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

Corporate overheadm

12,049

 


 

 

12,499

 


 

 

14,066

 


 

 

4

%

 

14

%

Depreciation and amortization

2,680

 


 

 

3,247

 


 

 

2,199

 


 

 

17

%

 

(22)

%

Acquisition and integration-related costsb

61

 


 

 

—

 


 

 

924

 


 

 

(100)

%

 

93

%

Restructuring costsc

318

 


 

 

2,316

 


 

 

835

 


 

 

86

%

 

62

%

Impairment chargese

—

 


 

 

1,071

 


 

 

1,921

 


 

 

100

%

 

100

%

Income (loss) from operations

$

26,447

 


 

 

$

(381

)


 

 

$

15,901

 


 

 

NM

 

 

66

%

 

 


 

 

 


 

 

 


 

 

 

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

 

Nine Months Ended

 

 

 

Year-over-
Year

 

 

 

September 30,


% of

 

September 30,


% of

 

 

 

% change

 

 

 

2021


Total

 

2020


Total

 

 

Fav (Unfav)

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

Revenue from services:

 


 

 

 


 

 

 


 

 

 

 

 

Nurse and Allied Staffing

$

985,335

 


95

%

 

$

569,306

 


92

%

 

 


 

 

73

%

 

 

Physician Staffing

50,638

 


5

%

 

51,505

 


8

%

 

 


 

 

(2)

%

 

 

 

$

1,035,973

 


100

%

 

$

620,811

 


100

%

 

 


 

 

67

%

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

Contribution income:l

 


 

 

 


 

 

 


 

 

 

 

 

Nurse and Allied Staffing

$

113,346

 


 

 

$

51,334

 


 

 

 


 

 

121

%

 

 

Physician Staffing

2,900

 


 

 

2,677

 


 

 

 


 

 

8

%

 

 

 

116,246

 


 

 

54,011

 


 

 

 


 

 

115

%

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

Corporate overheadm

40,326

 


 

 

36,993

 


 

 

 


 

 

(9)

%

 

 

Depreciation and amortization

7,132

 


 

 

10,472

 


 

 

 


 

 

32

%

 

 

Acquisition and integration-related costsb

985

 


 

 

77

 


 

 

 


 

 

NM

 

 

 

Restructuring costsc

2,391

 


 

 

5,210

 


 

 

 


 

 

54

%

 

 

Impairment chargese

2,070

 


 

 

16,082

 


 

 

 


 

 

87

%

 

 

Income (loss) from operations

$

63,342

 


 

 

$

(14,823

)


 

 

 


 

 

527

%

 

 

 

 


 

 

 


 

 

 


 

 

 

 

 

NM-Not meaningful.

 


 

 

 


 

 

 


 

 

 

 

 

Cross Country Healthcare, Inc.

Summary Condensed Consolidated Statements of Cash Flows

(Unaudited, amounts in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

September 30,

 

 

September 30,

 

 

June 30,

 

 

September 30,

 

September 30,

 

2021

 

 

2020

 

 

2021

 

 

2021

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash (used in) provided by operating activities

$

(2,831

)

 

 

$

(8,456

)

 

 

$

15,505

 

 

 

$

(12,253

)

 

$

25,275

 

Net cash used in investing activities

(1,888

)

 

 

(1,169

)

 

 

(26,286

)

 

 

(29,360

)

 

(3,659

)

Net cash (used in) provided by financing activities

(12,569

)

 

 

6,818

 

 

 

15,434

 

 

 

40,869

 

 

(19,183

)

Effect of exchange rate changes on cash

3

 

 

 

19

 

 

 

(14

)

 

 

(14

)

 

(19

)

Change in cash and cash equivalents

(17,285

)

 

 

(2,788

)

 

 

4,639

 

 

 

(758

)

 

2,414

 

Cash and cash equivalents at beginning of period

18,127

 

 

 

6,234

 

 

 

13,488

 

 

 

1,600

 

 

1,032

 

Cash and cash equivalents at end of period

$

842

 

 

 

$

3,446

 

 

 

$

18,127

 

 

 

$

842

 

 

$

3,446

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cross Country Healthcare, Inc.

Other Financial Data

(Unaudited)

 

 

Three Months Ended

 

 

Nine Months Ended

 

September 30,

 

 

September 30,

 

 

June 30,

 

 

September 30,

 

September 30,

 

2021

 

 

2020

 

 

2021

 

 

2021

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated gross profit marginn

22.4

%

 

 

24.7

%

 

 

21.9

%

 

 

22.0

%

 

23.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

Nurse and Allied Staffing statistical data:

 

 

 

 

 

 

 

 

 

 

 

 

FTEso

9,003

 

 

 

5,403

 

 

 

7,578

 

 

 

7,732

 

 

6,116

 

Average Nurse and Allied Staffing revenue per FTE per dayp

$

425

 

 

 

$

353

 

 

 

$

454

 

 

 

$

462

 

 

$

335

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Physician Staffing statistical data:

 

 

 

 

 

 

 

 

 

 

 

 

Days filledq

12,187

 

 

 

9,682

 

 

 

9,775

 

 

 

31,430

 

 

29,077

 

Revenue per day filledr

$

1,540

 

 

 

$

1,699

 

 

 

$

1,600

 

 

 

$

1,611

 

 

$

1,771

 

(a)


Adjusted EBITDA, a non-GAAP financial measure, is defined as net income (loss) attributable to common shareholders before interest expense, income tax expense (benefit), depreciation and amortization, acquisition and integration-related costs, restructuring costs, legal settlements and fees, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on disposal of fixed assets, gain or loss on sale of business, other expense (income), net, equity compensation, applicant tracking system costs, and includes net income attributable to noncontrolling interest in subsidiary. Adjusted EBITDA should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income attributable to common shareholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure as defined by the Company's credit facilities. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue.

(b)


Acquisition and integration-related costs include costs for legal and advisory fees for the WSG acquisition that closed on June 8, 2021, and valuation adjustments related to the contingent consideration liability for the Mediscan acquisition.

(c)


Restructuring costs are primarily comprised of employee termination costs, lease-related exit costs, and reorganization costs as part of planned cost savings initiatives.

(d)


Legal settlements and fees include legal settlement charges as presented on the consolidated statements of operations as well as legal fees pertaining to non-operational legal matters outside the normal course of operations which are included in selling, general and administrative expenses. For the nine months ended September 30, 2021, legal settlements and fees resulted in a net benefit of $1.2 million due to a recovery in the third quarter of $1.6 million. For the nine months ended September 30, 2020, we incurred $2.4 million in legal fees related to an ongoing legal matter outside the normal course of operations.

(e)


Impairment charges for the nine months ended September 30, 2021 were comprised of $1.9 million related to right-of-use assets and related property in connection with leases that were vacated during the second quarter and $0.1 million related to the write-off of a discontinued software development project. Impairment charges in 2020 of $16.1 million were comprised of $10.7 million primarily related to goodwill and other intangible assets for the former Search business and $5.4 million related to right-of-use assets and related property and equipment in connection with leases that were vacated during the second and third quarters. Rebranding impairments and accelerated amortization related to finite-lived trade names in connection with the rebranding initiatives.

(f)


Applicant tracking system costs are related to the Company's project to replace its legacy system supporting its travel nurse staffing business. These costs are reported in selling, general and administrative expenses on the consolidated statement of operations and included in corporate overhead in segment data.

(g)


Cross Country Talent Acquisition Group, LLC was controlled by the Company but not wholly owned. The Company recorded the ownership interest of the noncontrolling shareholder as noncontrolling interest in subsidiary. Effective December 31, 2020, the sole professional staffing services agreement held by this joint venture was terminated and, as a result, the Company dissolved Cross Country Talent Acquisition Group, LLC in the third quarter of 2021. The Company subsequently entered into a direct staffing agreement with the hospital system.

(h)


Adjusted EPS, a non-GAAP financial measure, is defined as net income (loss) attributable to common shareholders per diluted share before the diluted EPS impact of acquisition and integration-related costs, restructuring costs, legal settlements and fees, impairment charges, rebranding impairments and accelerated amortization, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, applicant tracking system costs, and nonrecurring income tax adjustments. Adjusted EPS should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful supplement to its reported EPS as an indicator of operating performance. Management believes it provides a more useful comparison of the Company's underlying business performance from period to period and is more representative of the future earnings capacity of the Company.

(i)


Non-recurring income tax adjustment for the nine months ended September 30, 2021 reflects a valuation allowance related to a state rate change as a result of the WSG acquisition.

(j)


Due to the net loss for the three and nine months ended September 30, 2020, 228 and 253 shares (in thousands) were excluded from diluted weighted average shares.

(k)


Segment data provided is in accordance with the Segment Reporting Topic of the FASB ASC. In the first quarter of 2021, the Company modified its reportable segments and now discloses two reportable segments - Nurse and Allied Staffing and Physician Staffing beginning in the first quarter of 2021. Revenue in the amount of $2.3 million and $7.7 million, respectively, and contribution loss of $0.3 million and $1.7 million, respectively, included in the previously-reported Search segment have been reclassified to Nurse and Allied Staffing for the three and nine months ended September 30, 2020.

(l)


Contribution income is defined as income (loss) from operations before depreciation and amortization, acquisition and integration-related costs, restructuring costs, legal settlement charges, impairment charges, and corporate overhead. Contribution income is a financial measure used by management when assessing segment performance.

(m)


Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives).

(n)


Gross profit is defined as revenue from services less direct operating expenses. The Company's gross profit excludes allocated depreciation and amortization expense. Gross profit margin is calculated by dividing gross profit by revenue from services.

(o)


FTEs represent the average number of Nurse and Allied Staffing contract personnel on a full-time equivalent basis.

(p)


Average revenue per FTE per day is calculated by dividing Nurse and Allied Staffing revenue, excluding permanent placement, per FTE by the number of days worked in the respective periods.

(q)


Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by 8 hours.

(r)


Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented.

 

Contacts

Cross Country Healthcare, Inc.
William J. Burns, Executive Vice President & Chief Financial Officer
561-237-2555
wburns@crosscountry.com

EX-101.SCH 3 ccrn-20211103.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ccrn-20211103_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 ccrn-20211103_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 cc_logo.jpg begin 644 cc_logo.jpg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end XML 7 a52520247_htm.xml IDEA: XBRL DOCUMENT 0001141103 2021-11-03 2021-11-03 false 0001141103 8-K 2021-11-03 CROSS COUNTRY HEALTHCARE INC DE 0-33169 13-4066229 6551 Park of Commerce Boulevard N.W. Boca Raton FL 33487 561 998-2232 Common stock, par value $0.0001 per share CCRN NASDAQ false false false false false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 03, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 03, 2021
Entity Registrant Name CROSS COUNTRY HEALTHCARE INC
Entity Incorporation, State or Country Code DE
Entity File Number 0-33169
Entity Tax Identification Number 13-4066229
Entity Address, Address Line One 6551 Park of Commerce Boulevard
Entity Address, Address Line Two N.W.
Entity Address, City or Town Boca Raton
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33487
City Area Code 561
Local Phone Number 998-2232
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001141103
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol CCRN
Security Exchange Name NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://crosscountryhealthcare.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports a52520247.htm a52520247ex991.htm ccrn-20211103.xsd ccrn-20211103_lab.xml ccrn-20211103_pre.xml cc_logo.jpg http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a52520247.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "a52520247.htm" ] }, "labelLink": { "local": [ "ccrn-20211103_lab.xml" ] }, "presentationLink": { "local": [ "ccrn-20211103_pre.xml" ] }, "schema": { "local": [ "ccrn-20211103.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ccrn", "nsuri": "http://crosscountryhealthcare.com/20211103", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a52520247.htm", "contextRef": "c20211103to20211103", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "a52520247.htm", "contextRef": "c20211103to20211103", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://crosscountryhealthcare.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001157523-21-001322-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001157523-21-001322-xbrl.zip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Ϣ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end